MarketInOut Stock Screener Log In | Sign Up
 

Theriva Biologics Inc

NYSE • Healthcare • Biotechnology • Quote as of 06/12/2026
Theriva Biologics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization14.5 mln
Float45.14 mln
Earnings Date08/12/2026

Piotroski F-Score

3 / 9
Below average

Relative Strength

90 / 100
Top performer

Debt / Equity

0.24
Very low leverage

ROE

-169
Deeply negative

Dividend Yield

0.00%
No dividend

DPS

0.00
No dividend

Business Description

Theriva Biologics is a US-based clinical-stage company focused on developing new treatments for cancer and related conditions where patients currently have few effective options. Its most advanced program, VCN-01, is an engineered virus designed to target and destroy tumor cells, and is being tested across multiple cancer types including pancreatic, ovarian, and head and neck cancers. The company is also advancing a pipeline of therapies aimed at protecting patients from serious complications that can arise during cancer treatment, such as gut damage and dangerous infections caused by antibiotics. Theriva operates from its headquarters in Rockville, Maryland, and works with partners including Washington University School of Medicine to advance its clinical programs.

Key Fundamentals

EPS-0.58
ROE-169
RPS0.01
ROIC-92.21
ROA-61.20
EBITDA, mln-21.66
EV / EBITDA-0.13
EV / EBIT-0.12
Revenue, mln0.30
EV / Revenue9.06

Financial Strength

Altman Z-Score-14.49
Piotroski F-Score 3 / 9
Short Ratio1.12
Short % of Float5.94

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 19.04% 97 / 100   
1 Month -7.94% 21 / 100   
2 Months 68.03% 95 / 100   
6 Months 37.16% 90 / 100   
1 Year -42.68% 15 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us